Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Next Previous
Drug Profile

Bictegravir/emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: B/F/TAF; BIC/FTC/TAF; Bictegravir/F/TAF; Bictegravir/tenofovir-alafenamide/emtricitabine; Biktarvy; Emtricitabine/bictegravir/tenfovir-alafenamide; Emtricitabine/GS 9883/tenofovir alafenamide; Emtricitabine/tenofovir-alafenamide/GS-9883; Emtricitabine/tenofovir-alafenamine/bictegravir; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide; J05AR20; Tenofovir-alafenamide/bictegravir/emtricitabine; Tenofovir-alafenamide/emtricitabine/bictegravir; Tenofovir-alafenamide/emtricitabine/GS-9883; Tenofovir-alafenamide/GS-9338/emtricitabine

Latest Information Update: 27 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Deoxyribonucleosides; Oxazepines; Purines; Pyrazines; Pyridones; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase I inhibitors; DNA polymerase II inhibitors; HIV integrase inhibitors; HIV reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III Hepatitis B

Most Recent Events

  • 12 Mar 2025 Efficacy and adverse events data from a phase III ALLIANCE trial in Hepatitis B and HIV infection released by Gilead Scienced
  • 16 Oct 2024 Updated efficacy and adverse events data from a phase II trial in HIV infection presented at the IDWeek 2024 (IDW-2024)
  • 17 Jun 2024 Gilead Sciences in collaboration with Janssen Pharmaceuticals completes the LAPTOP phase III trial for HIV-1 infections in Belgium, France, Germany, Ireland, Italy, the UK and Spain (NCT03696160)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top